NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 103 filers reported holding NURIX THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,627,651 | +78576.6% | 1,224,892 | 0.0% | 0.51% | -9.7% |
| Q2 2023 | $12,237 | +12.5% | 1,224,892 | 0.0% | 0.57% | +6.4% |
| Q1 2023 | $10,877 | -99.9% | 1,224,892 | 0.0% | 0.53% | -24.7% |
| Q4 2022 | $13,449,314 | -15.7% | 1,224,892 | 0.0% | 0.71% | -21.0% |
| Q3 2022 | $15,960,000 | +2.8% | 1,224,892 | 0.0% | 0.90% | -8.6% |
| Q2 2022 | $15,519,000 | -9.6% | 1,224,892 | 0.0% | 0.98% | +11.5% |
| Q1 2022 | $17,161,000 | -51.6% | 1,224,892 | 0.0% | 0.88% | -35.9% |
| Q4 2021 | $35,461,000 | -3.4% | 1,224,892 | 0.0% | 1.38% | +7.4% |
| Q3 2021 | $36,698,000 | +12.9% | 1,224,892 | 0.0% | 1.28% | +11.8% |
| Q2 2021 | $32,496,000 | -14.7% | 1,224,892 | 0.0% | 1.15% | -11.2% |
| Q1 2021 | $38,082,000 | -5.4% | 1,224,892 | 0.0% | 1.29% | -0.2% |
| Q4 2020 | $40,274,000 | -14.8% | 1,224,892 | -9.6% | 1.30% | -20.7% |
| Q3 2020 | $47,282,000 | – | 1,354,392 | – | 1.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |